Statements (55)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:peginterferon
|
| gptkbp:activities |
immune modulation
|
| gptkbp:approves |
gptkb:2001
gptkb:FDA with sterile water |
| gptkbp:availability |
prescription only
|
| gptkbp:brand |
gptkb:Pegintron
|
| gptkbp:can_be_used_with |
gptkb:ribavirin
|
| gptkbp:class |
antiviral
|
| gptkbp:clinical_trial |
HCV treatment studies
|
| gptkbp:contraindication |
gptkb:healthcare_organization
decompensated liver disease hypersensitivity to peginterferon |
| gptkbp:dosage_form |
injection
|
| gptkbp:duration |
24 to 48 weeks
|
| gptkbp:formulation |
lyophilized powder
|
| https://www.w3.org/2000/01/rdf-schema#label |
Pegintron
|
| gptkbp:indication |
HCV genotype 1
HCV genotype 2 HCV genotype 3 HCV genotype 4 HCV genotype 5 HCV genotype 6 |
| gptkbp:ingredients |
peginterferon alfa-2b
|
| gptkbp:interacts_with |
other immunosuppressants
CY P450 substrates |
| gptkbp:is_monitored_by |
liver function tests
complete blood count thyroid function tests |
| gptkbp:is_used_for |
chronic hepatitis C
|
| gptkbp:lifespan |
approximately 50 hours
|
| gptkbp:manager |
subcutaneous injection
|
| gptkbp:manufacturer |
gptkb:Schering-Plough
|
| gptkbp:marketed_as |
Pegintron Injection
|
| gptkbp:packaging |
vial
|
| gptkbp:population |
adults
children over 5 years |
| gptkbp:previous_name |
peginterferon alfa-2b
|
| gptkbp:price |
varies by region
|
| gptkbp:rounds |
renal and hepatic
|
| gptkbp:safety_features |
well-studied
|
| gptkbp:side_effect |
gptkb:historical_event
gptkb:fandom fatigue headache nausea insomnia injection site reactions thrombocytopenia flu-like symptoms neutropenia |
| gptkbp:storage |
refrigerated
|
| gptkbp:type_of_care |
important for treatment success
|